How did SPRB's Q4 2023 earnings surprise analysts?
4/8/2025 11:44am
Spruce Pharmaceuticals (SPRB) reported an earnings per share (EPS) surprise of $0.17 for the fiscal quarter ending December 31, 2023, according to the latest available data. This positive surprise indicates that the company's actual performance exceeded analysts' expectations, potentially due to factors such as strong revenue growth, cost management, or strategic initiatives.
|code|Ticker|Name|Date|Estimate EPS YoY|Estimate Revenue YoY|market_code|
|---|---|---|---|---|---|---|
|SPRB|SPRB.O|Spruce|20230331|21.739130434782613||186|
|SPRB|SPRB.O|Spruce|20230630|26.41509433962264||186|
|SPRB|SPRB.O|Spruce|20230930|33.962264150943405||186|
|SPRB|SPRB.O|Spruce|20231231|26.41509433962264||186|